Strides Pharma Science Arm Gets Usfda Nod For Drug To Treat Overactive Bladder
Strides Pharma Science Friday Said Its Step-Down Wholly-Owned Subsidiary Has Received Approval From The Us Health Regulator For Solifenacin Succinate Tablets, Used To Treat Overactive Bladder.The Approved Product Is A Generic Version Of Vesicare Tablets Of Astellas Pharma Us, Inc.Strides Pharma Global, Singapore, Has Received Approval For Solifenacin Succinate Tablets, 5 Mg And 10 Mg, From The United States Food And Drug Administration (Usfda), Strides Pharma Science Said In A Regulatory Filing.Citing Iqvia Data, The Company Said The Us Market For Solifenacin Succinate Tablets, 5 Mg And 10 Mg Is Approximately Usd 820 Million.Strides Said The Product Will Be Manufactured At Alathur Facility In Chennai And Will Be Marketed By Strides Pharma In The Us Market.
Let’s apply Data-Driven Pricing to Your APIs
Sick and tired of always wondering if you are being asked to pay the right price for your APIs? This empowers you with the answers you need to make the right decisions in the Global API market.
Chemxpert Database is one of the biggest and most comprehensive directories of pharma and chemicals, manufacturers, suppliers and information. Provided with current information on prices, demand and transactions, it gives you instant feedback on whether you are buying what is right and at the right time.
Start using market intelligence today and allow yourself to be in control in the API market.
Check it out today and make more informed sourcing decisions!
Learn More!